Far Infrared Radiation Treatment for Uterine Fibroids
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00574418|
Recruitment Status : Unknown
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was: Active, not recruiting
First Posted : December 17, 2007
Last Update Posted : January 5, 2009
|Condition or disease||Intervention/treatment||Phase|
|Leiomyoma||Radiation: Far Infrared Radiation (5μm to 20μm wavelength)||Phase 1|
Uterine fibroids are the most common neoplasms of the female pelvis. These benign tumors are generally oval in shape and often highly vascular. On MR imaging exams, uterine fibroids are easily identifiable. They occur in 20-25% of women of reproductive age and can cause a variety of problems generally described as either bleeding or mass effects from the fibroid.
We are postulating that energy specific electromagnetic radiation of the uterus will shrink the benign tumors.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Uterine Fibroids|
|Study Start Date :||January 2006|
|Estimated Primary Completion Date :||March 2008|
|Estimated Study Completion Date :||September 2008|
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
Other Name: Far infrared radiation
- The primary end point is to determine the therapeutic effects of far infrared radiation on uterine fibroids [ Time Frame: 2 years and 9 months ]
- The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other related uterine conditions, for example, bleeding. [ Time Frame: Two years and nine months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00574418
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Principal Investigator:||Ken B Nedd, M.D.||GAAD Medical Research Institute Inc.|
|Study Director:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|